BUSINESS COMBINATION (Details Narrative) - USD ($) |
6 Months Ended | |||
|---|---|---|---|---|
Mar. 04, 2025 |
Jun. 30, 2026 |
Dec. 31, 2025 |
Jul. 29, 2025 |
|
| BUSINESS COMBINATION | ||||
| Sellers retention description | amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra | |||
| Common stock shares issued | 500,000 | 500,000 | ||
| Closing market price | $ 0.31 | |||
| Common stock price per share | $ 0.31 | $ 0.001 | $ 0.001 | |
| Common stock purchased | 500,000 | |||
| Exercise price | $ 1.00 | $ 0.35 | ||
| Fair value of stock issued | $ 153,500 | |||
| Royalty payments | $ 108,260 | |||
| Upfront purchase price | $ 400,000 | $ 392,441 | ||
| Discounted at the risk-free rate | 4.04% | |||
| Discounted at required metric risk premium | 24.09% |